TOP > 外国特許検索 > IgG-BINDING PEPTIDE

IgG-BINDING PEPTIDE NEW

外国特許コード F170009267
整理番号 (S2016-0552-N0)
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP010115
国際公開番号 WO 2017159655
国際出願日 平成29年3月14日(2017.3.14)
国際公開日 平成29年9月21日(2017.9.21)
優先権データ
  • 特願2016-049153 (2016.3.14) JP
発明の名称 (英語) IgG-BINDING PEPTIDE NEW
発明の概要(英語) [Problem] To provide a peptide that binds strongly to immunoglobulin G (IgG). [Solution] This peptide has the amino acid sequence represented by SEQ ID NO:1. In said amino acid sequence: the 16th amino acid (X16) from the amino acid of the N-terminal is L, M, I or F; the 17th amino acid (X17) from the amino acid of the N-terminal is R, K, Y or Q; the 19th amino acid (X19) from the amino acid of the N-terminal is an arbitrary amino acid; the 20th amino acid (X20) from the amino acid of the N-terminal is an arbitrary amino acid; the 26th amino acid (X26) from the amino acid of the N-terminal is G or E, or is deleted; the 29th amino acid (X29) from the amino acid of the N-terminal is an arbitrary amino acid; the 30th amino acid (X30) from the amino acid of the N-terminal is an arbitrary amino acid; the 32nd amino acid (X32) from the amino acid of the N-terminal is an arbitrary amino acid; and the 33rd amino acid (X33) from the amino acid of the N-terminal is an arbitrary amino acid.
特許請求の範囲(英語) [claim1]
1. The peptide which possesses the amino acid arrangement of arrangement number 1.
However, during the same amino acid arranging,
16th amino acid (X16) L, M and I or is F from the amino acid of N end,
17th amino acid (X17) is R, K, Y or Q from the amino acid of N end,
19th amino acid (X19) it is optional amino acid from the amino acid of N end,
20th amino acid (X20) it is optional amino acid from the amino acid of N end,
26th amino acid (X26) G or E or we have been deficient from the amino acid of N end,
29th amino acid (X29) it is optional amino acid from the amino acid of N end,
30th amino acid (X30) it is optional amino acid from the amino acid of N end,
32nd amino acid (X32) it is optional amino acid from the amino acid of N end,
33rd amino acid (X33) is optional amino acid from the amino acid of N end.
[claim2]
2. The peptide which possesses the amino acid arrangement of arrangement number 1.
However, during the same amino acid arranging,
16th amino acid (X16) L, M and I or is F from the amino acid of N end,
17th amino acid (X17) is R, K, Y or Q from the amino acid of N end,
19th amino acid (X19) V, A and L, M, F or is I from the amino acid of N end,
20th amino acid (X20) it is optional amino acid from the amino acid of N end,
26th amino acid (X26) G or E or we have been deficient from the amino acid of N end,
29th amino acid (X29) I, A and L, V and M or is F from the amino acid of N end,
30th amino acid (X30) is optional amino acid from the amino acid of N end,
32nd amino acid (X32) A, L and F, is M or I from the amino acid of N end,
33rd amino acid (X33) is N, D, H, A, T or G from the amino acid of N end,
In claim 1 peptide of statement.
[claim3]
3. During amino acid arranging of arrangement number 1,
16th amino acid (X16) L or is M from the amino acid of N end,
17th amino acid (X17) is R or K from the amino acid of N end,
19th amino acid (X19) V, A and L or is M from the amino acid of N end,
29th amino acid (X29) I, A and L, is V or M from the amino acid of N end,
32nd amino acid (X32) is A, L or F from the amino acid of N end,
33rd amino acid (X33) is N, D, H, A or T from the amino acid of N end,
In claim 1 peptide of statement.
[claim4]
4. During amino acid arranging of arrangement number 1,
16th amino acid (X16) L or is M from the amino acid of N end,
17th amino acid (X17) is R or K from the amino acid of N end,
19th amino acid (X19) as for the A is V from the amino acid of N end,
20th amino acid (X20) is G, Q, R or A from the amino acid of N end,
26th amino acid (X26) it is G from the amino acid of N end,
29th amino acid (X29) I, A and L or is V from the amino acid of N end,
30th amino acid (X30) is A, T, Q, E or S from the amino acid of N end,
32nd amino acid (X32) is A, L or F from the amino acid of N end,
33rd amino acid (X33) is A or N from the amino acid of N end,
In claim 1 peptide of statement.
[claim5]
5. During the aforementioned amino acid arranging, from the amino acid of N end 12th amino acid (I12) either of the claim 1-4 which is optional amino acid in 1 sections the peptide of statement.
[claim6]
6. During the aforementioned amino acid arranging, from the amino acid of N end 12th amino acid (I12) either of the claim 1-4 which is A in 1 sections the peptide of statement.
[claim7]
7. During the aforementioned amino acid arranging, from the amino acid of N end 39th amino acid (L39) either of the claim 1-6 which is A in 1 sections the peptide of statement.
[claim8]
8. During the aforementioned amino acid arranging, from N end the cystein of 5th cystein and C end disulfide either of the claim 1-7 which is connected in 1 sections the peptide of statement.
[claim9]
9. During the aforementioned amino acid arranging, from N end 5th cystein and/or either of the claim 1-7 where the cystein of C end is substituted with optional amino acid in 1 sections the peptide of statement.
[claim10]
10. During the aforementioned amino acid arranging, from N end 5th cystein and/or either of the claim 1-7 where the cystein of C end is substituted with the glutamine in 1 sections the peptide of statement.
[claim11]
11. The dissociation constant for human immunoglobulin G (K [D]), below 3000nM, desirably below 1000nM, desirably either of the claim 1-10 which is below 100nM in 1 sections the peptide of statement.
[claim12]
12. The peptide which possesses each amino acid arrangement of the arrangement number 2-51.
[claim13]
13. The peptide which possesses each amino acid arrangement of the arrangement number 2-51, from N end of amino acid arrangement the cystein of C end of 5th cystein and the same amino acid arrangement disulfide it connects.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA PREFECTURE UNIVERSITY
  • 発明者(英語)
  • FUJII IKUO
国際特許分類(IPC)
指定国 (WO2017159655)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close